Catalyst Event
Shanghai Fosun Pharmaceutical (Group) Co Ltd (2196) · Other
From Akros SCHK HK-Global Brain-Computer Interface Index (ASHGBCI)
5/29/2026, 12:00:00 AM
Announced that subsidiary Shanghai Henlius Biotech's Pertuzumab Injection (brand name 汉倍优®) was approved for marketing by China's NMPA. Low importance as subsidiary product approvals typically have a limited price impact (<5%).
Korean Translation
자회사 상하이 헨리우스 바이오텍의 유방암 치료용 바이오시밀러 퍼투주맙 주사제(브랜드명 汉倍优®)가 중국 NMPA 판매 허가를 획득함. 자회사 제품 허가에 따른 주가 영향은 1~5% 수준으로 제한적일 것으로 예상됨.
Related Recent Events
Ambu A/S (AMBUB) · Earnings Release
Q3 2025/26 earnings release scheduled. (Low importance estimated for a routine scheduled event).
8/26/2026, 12:00:00 AM
Boston Scientific Corp (BSX) · Earnings Release
Q2 2026 earnings results and conference call for July 29, 2026, before market open scheduled
7/29/2026, 12:00:00 AM
Integer Holdings Corp (ITGR) · Earnings Release
Analysts forecast the next quarterly earnings release for 2026-07-23 estimated. Estimated Medium importance as earnings reports typically drive significant price volatility.
7/23/2026, 12:00:00 AM
Alphabet Inc (GOOGL) · Earnings Release
Alphabet Q2 2026 earnings release scheduled for July 22, 2026, with analysts forecasting EPS of approximately $2.85-$2.87 forecasted.
7/22/2026, 12:00:00 AM
Abbott Laboratories (ABT) · Earnings Release
Abbott is expected to announce its Q2 2026 earnings results on July 16, 2026. This key quarterly financial update is estimated to have a moderate price impact of at least 5%, scheduled.
7/16/2026, 12:00:00 AM
Pharmaron Beijing Co Ltd (3759) · Other
The ex-dividend date for the RMB 0.20 per share final dividend on July 7, 2026, with payment on August 7, 2026; market reaction is estimated at Low as the payout is within expected ranges scheduled.
7/7/2026, 12:00:00 AM